Detalhe da pesquisa
1.
Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial.
Mov Disord
; 37(3): 513-524, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34859493
2.
Using Clinical Scales and Digital Measures to Explore Falls in Patients with Lewy Body Dementia.
Digit Biomark
; 7(1): 54-62, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37404864
3.
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator, in Patients With Parkinson Disease.
Clin Pharmacol Drug Dev
; 11(3): 324-332, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34664427
4.
Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body Dementia.
J Parkinsons Dis
; 12(6): 1991-2004, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35694933